Search
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approvedLiothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. … [T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]
Chlormerodrin Hg-197
go.drugbank.com/drugs/DB09406ApprovedChlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.
Canakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalCanakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). … be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by
Luliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
Inositol
go.drugbank.com/drugs/DB13178ApprovedInvestigationalWithdrawn[L2560] Inositol can be found as an ingredient of OTC products by Health Canada but all current product whose main ingredient is inositol are discontinued. … Inositol is a collection of nine different stereoisomers but the name is usually used to describe only the most common type of inositol, myo-inositol.
Mixtures: Palm Spring's PM Form TabDatopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]
Pidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729]. … Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide … A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the US
Trioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnIt is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. … The photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis.
Bictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.